Actively Recruiting
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
Led by Yale University · Updated on 2025-05-04
15
Participants Needed
1
Research Sites
233 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how drivers of gluconeogenesis and lipemia (specifically measured as visceral fat ratio, insulin resistance, and postprandial lipemia,) that contribute to cardiometabolic risk in T1D change over time.
CONDITIONS
Official Title
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form provided
- Willing to comply with all study procedures and available for the study duration
- Male or female aged 18 to 30 years
- Diagnosed with type 1 diabetes for at least 12 months and BMI less than 25 kg/m2
- HbA1c 10% or less
- Use of continuous glucose monitoring (CGM)
- No known lab safety issues such as baseline creatinine greater than 1.0 mg, triglycerides over 400 mg/dl, or ALT more than 3.5 times the upper normal limit in the past year
You will not qualify if you...
- Current use of additional diabetes or anti-obesity medications
- Insulin dose less than 0.5 units/kg/day
- Use of lipid-lowering medications other than statins or omega-3 products
- Does not meet MRI safety criteria or has claustrophobia
- Known liver disease other than non-alcoholic steatosis or fatty liver disease
- Known kidney impairment
- Pregnancy, breastfeeding, or planning pregnancy during study
- Anemia or blood conditions affecting HbA1c or other medical conditions preventing participation
- Use of investigational drugs within the past month
- History or allergy to corn
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yale Pediatric Diabetes Research
New Haven, Connecticut, United States, 06520
Actively Recruiting
Research Team
R
Rehema Mtawali
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here